Prestige BioPharma (950210) Fundamentals 2026 — Revenue Analysis | SniperIQ
Prestige BioPharma (950210) is a SG-listed Healthcare company in Biotechnology with a market capitalization of ₩306.5B, trading at ₩5100.00 on the KSC. This SniperIQ fundamentals page covers Prestige BioPharma's valuation, profitability (net margin -354.8%), revenue (₩14.3B in FY2024), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Prestige BioPharma's market cap?
Prestige BioPharma (950210) has a market capitalization of approximately ₩306.5B, trading at ₩5100.00 on the KSC. Market cap moves with the live share price.
What is Prestige BioPharma's P/E ratio?
Prestige BioPharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Prestige BioPharma?
Prestige BioPharma runs a net profit margin of -354.8%, a gross margin of -211.1%, and an operating margin of -521.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Prestige BioPharma generate?
Prestige BioPharma reported revenue of ₩14.3B for fiscal year 2024, with net income of ₩22.3B and earnings per share (EPS) of 370.61. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Prestige BioPharma pay a dividend?
Prestige BioPharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Prestige BioPharma financially healthy?
Prestige BioPharma carries a debt-to-equity ratio of 0.18x and a current ratio of 0.85x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Prestige BioPharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Prestige BioPharma (950210) the key facts are: market cap ₩306.5B, revenue ₩14.3B, 52-week range 4945-15900. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Prestige BioPharma's full fundamentals live
Get Prestige BioPharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.